Transgene Biotek is locked at upper circuit limit at Rs. 3.88, up by 0.18 points or 4.86% from its previous closing of Rs. 3.70 on the BSE.
The scrip opened at Rs. 3.88 and has touched a high and low of Rs. 3.88 and Rs. 3.88 respectively. So far 24261 shares were traded on the counter.
The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 4.26 on 09-Oct-2018 and a 52 week low of Rs. 1.81 on 06-Jul-2018.
Last one week high and low of the scrip stood at Rs. 3.88 and Rs. 3.23 respectively. The current market cap of the company is Rs. 29.40 crore.
The promoters holding in the company stood at 23.64%, while Non-Institutions held 76.36% stake in the company.
Transgene Biotek has been granted United State of America patent on technology for Oral delivery of Insulin and Insulin analogues.
This patent is a feather in the cap of Transgene Biotek's list of global patents. This intimation of patent being granted by USA will strengthen the company's management to justifiably increase its monetary value of its technology for oral delivery of Insulin and its analogues. With emergence of Insulin analogues across the globe from several large pharma companies, Transgene's oral delivery technology shall provide a new dimension for such molecules to deliver them through a convenient and increased patient compliant oral route.
Transgene Biotek (TBL) is engaged in manufacturing drugs.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 435.70 |
| Indegene | 486.80 |
| CMS Info Systems | 318.00 |
| JITF Infralogistics | 338.00 |
| Sagility | 42.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: